CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 205 enrolled
Drug / intervention
Golimumabdrug
Likely dose
Golimumab 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02092285
NCT02092285Phase 4Completed
CompareCT.gov

Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis

Merck Sharp & Dohme LLC·interventional·Posted Mar 20, 2014·Updated Mar 15, 2019

In Brief

A Phase 4 clinical trial evaluating Golimumab for Ulcerative Colitis. Completed, enrolled 205 participants across 1 site.

Detailed Summary

The primary objective of this study is to evaluate the efficacy of golimumab in maintaining a clinical response in participants with moderate-to-severe ulcerative colitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 20, 2014
Enrollment StartMay 9, 2014
Primary CompletionMay 25, 2016
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.3 years ago

Interventions

Golimumabdrug

50mg or 100mg solution for injection; subcutaneous injection